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The apolipoprotein AV gene (APOA5) is a key determi-
nant of plasma triglyceride levels, a major risk factor for
coronary artery disease and a biomarker for the meta-
bolic syndrome. Since thyroid hormones influence very
low density lipoprotein triglyceride metabolism and
clinical studies have demonstrated an inverse correla-
tion between thyroid status and plasma triglyceride lev-
els, we examined whether APOA5 is regulated by thy-
roid hormone. Here we report that 3,5,3-triiodo-L-
thyronine (T3) and a synthetic thyroid receptor  (TR)
ligand increase APOA5 mRNA and protein levels in
hepatocytes. Our data revealed that T3-activated TR di-
rectly regulates APOA5 promoter through a functional
direct repeat separated by four nucleotides (DR4). Inter-
estingly, we show that upstream stimulatory factor 1, a
transcription factor associated with familial combined
hyperlipidemia and elevated triglyceride levels in hu-
mans, and upstream stimulatory factor 2 cooperate with
TR, resulting in a synergistic activation of APOA5 pro-
moter in a ligand-dependent manner via an adjacent
E-box motif. In rats, we observed that apoAV levels de-
clines with thyroid hormone depletion but returned to
normal levels upon T3 administration. In addition, treat-
ments with a TR-selective agonist increased apoAV
and diminished triglyceride levels. The identification of
APOA5 as a T3 target gene provides a new potential
mechanism whereby thyroid hormones can influence
triglyceride homeostasis. Additionally, these data sug-
gest that TRmay be a potential pharmacological target
for the treatment of hypertriglyceridemia.
A recent survey estimated that 30% of the United States
adult population exhibits hypertriglyceridemia (1), an inde-
pendent risk factor for coronary artery disease (2) and a key
feature of the highly prevalent metabolic syndrome (1, 3).
Therefore, understanding the factors that regulate triglyceride
(TG)1 levels is of major interest and may provide new opportu-
nities for therapeutic intervention in atherogenic dyslipidemia.
Elevation of plasma TG is associated with hypothyroidism
(4–8). Indeed, hypertriglyceridemia is clearly associated with
hypothyroidism in obese patients, who are characterized by
attenuated rates of clearance of very low density lipoprotein
(VLDL)-TG, relative to those in obese euthyroid subjects (6).
Such elevation in TG levels has been attributed to low lipopro-
tein lipase (LPL) (9) or low hepatic triglyceride lipase activities
(6, 10, 11). In contrast, hyperthyroid patients exhibit elevated
rates of clearance of VLDL and normal or decreased circulating
TG levels (6), whereas treatment with thyroid hormones (TH)
is associated with elevation in both LPL and hepatic triglycer-
ide lipase activities (9, 10, 11) and concomitantly with a tend-
ency to TG lowering (6, 9, 11). At present, the molecular mech-
anisms by which TH may regulate lipase activities and
circulating TG levels in humans remain to be defined.
3,5,3-Triiodo-L-thyronine (T3) exerts its biological actions
through binding to specific nuclear receptors that modulate
gene expression (12). Typically, the T3 receptor (TR) complexes
with the retinoid X receptor (RXR) to form a heterodimer that
binds to specific DNA sequence elements known as TREs,
composed of two half-core PuGGTCA motifs with specific nu-
cleotide spacing and orientation (13). There are several TRs,
which are encoded by two distinct genes, TR (NR1A1) and
TR (NR1A2). The TR gene gives rise to the ligand-binding
protein TR1 and splice variants that do not bind T3. Several
amino-terminal protein variants are produced from the TR
gene: TR1; TR2, which is largely restricted to anterior pitu-
itary and hypothalamus (12); and the two recently identified,
low level expressed, TR3 and TR3 (14).
The widely expressed isoforms TR1 and TR1 have diver-
gent N-terminal regions but display remarkably sequence ho-
mology throughout the rest, especially in their DNA binding
domains (12, 15). As a consequence, both isoforms can bind T3
with similar affinities, and heterodimers of RXR and either TR
isoform recognize the same motifs on DNA (12). Despite their
structural similarities, distinct patterns of expression of TRs
may account for isoform-specific phenotypic functional differ-
ences observed in in vivo investigations (12). In the liver, TR1
is the predominant receptor isoform, representing 80% of T3-
binding activity (16, 17). T3 influences lipid metabolism
through the hepatic regulation of some key TRE-bearing genes,
including the lipogenic fatty acid synthase and malic enzyme
(18, 19), the mitochondrial fatty acid oxidation rate-controlling
enzyme carnitine palmitoyltransferase-I (CPT-I) (20, 21),
the rate-limiting enzyme in bile acid synthesis CYP7A1 (22),
and the sterol regulatory element-binding protein-2, which in
turn activates the low density lipoprotein receptor (LDLr) and
other genes directly involved in cholesterol homeostasis (23).
The administration of thyroid hormones lowers plasma choles-
terol in hypothyroid patients. Unfortunately, the natural TH
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cannot be used therapeutically to treat hypercholesterolemia in
euthyroid individuals because they have undesirable effects in
the heart, where TR1 is the predominant isoform (12). These
differences in TR isoform expression, together with the fact
that TR1 and TR1 isoforms can bind TH analogs with subtle
differences in affinity, have spawned attempts to develop thy-
romimetics with higher selectivity toward TR1 versus TR1
that may have cholesterol-lowering effects but minimal cardiac
toxicity (12).
Apolipoproteins (apo) play a determinant role in lipid home-
ostasis. Alterations in the levels of these functionally special-
ized proteins dramatically influence plasma lipid concentra-
tions. Recently, the gene coding for a new apolipoprotein family
member, APOA5, was identified 30 kb proximal to the APOA1/
C3/A4 gene cluster and shown to be a major determinant of
plasma TG levels (24, 25). Mice expressing a human APOA5
transgene (24) or injected with adenoviral vectors overexpress-
ing mouse APOA5 (26) exhibit reduction in plasma TG concen-
trations to one-third the levels of control mice. Conversely, in
knock-out mice lacking APOA5, plasma TG levels were 4-fold
elevated compared with their wild-type littermates (24). In
humans, common polymorphisms across the APOA5 locus have
been associated with elevated plasma TG concentrations (24,
27), familial combined hypertriglyceridemia (28), and in-
creased risk of cardiovascular disease (29, 30). Furthermore,
inherited apoAV deficiency is associated with severe hypertrig-
lyceridemia in humans (31). ApoAV is a highly hydrophobic
protein mainly expressed in liver that circulates at low concen-
trations associated with high density lipoprotein (24, 25); in
addition, apoAV appears to reduce plasma TG by inhibiting
hepatic VLDL-TG production and stimulating LPL-mediated
VLDL-TG hydrolysis (32).
Inasmuch as apoAV concentration is a key determinant of
plasma TG levels and since the apolipoprotein gene family is
highly regulated at the transcriptional level (33), recent re-
search has been oriented to the identification of factors that
control APOA5 expression. Little is known regarding the tran-
scriptional regulation of this newly discovered gene, although it
has been shown to date that APOA5 is regulated by peroxisome
proliferator-activated receptor- (NR1C1), farnesoid X-acti-
vated receptor (NR1H4), and sterol regulatory element-binding
protein-1c, all of which are transcription factors directly impli-
cated in triglyceride metabolism (34–36).
Since T3 influences VLDL-TG metabolism, we investigated
whether T3 might regulate APOA5 expression. In this study,
we provide evidence that T3 induces APOA5 expression. Fur-
thermore, our findings reveal that TR directly regulates
APOA5 in a ligand-dependent manner via a functional TRE
within the promoter. In addition, in rats in vivo, apoAV content
correlated with thyroid status, and moreover a TR ligand
increased apoAV and simultaneously diminished TG levels.
Therefore, our findings provide evidence for molecular cross-
talk between thyroid status and intravascular TG metabolism.
EXPERIMENTAL PROCEDURES
Plasmids—Constructs p-1422/18hAvLUC, p-617/18hAvLUC,
p-437/18hAvLUC, p-242/18hAvLUC, and p-82/18hAvLUC con-
taining the corresponding sequences of the 5-flanking region of the
human APOA5 gene cloned in front of the promoterless firefly (Photinus
pyralis) luciferase gene have been previously described (35). Site-di-
rected mutagenesis of the construct p-617/18hAvLUC was performed
using the QuikChangeTM site-directed mutagenesis kit (Stratagene)
according to the recommendations of the manufacturer and two pairs of
oligonucleotides containing mutations corresponding, respectively, to nt
109C3T/108A3T/101G3A/100T3A and to nt 80A3C/
77T3C of the human APOA5 promoter. The vector pGL3-TK contains
a fragment corresponding to nt 109 to 20 of the thymidine kinase
(TK) gene promoter of herpes simplex virus (36) subcloned into the
BglII/HindIII sites of pGL3-basic vector. The reporter plasmids
p(AVDR4)n-TK (n  1–5) were generated by insertion of 1–5 copies of a
double-stranded oligonucleotide containing wild type (5-GAT CCT
GGG AGG CAG CTG AGG TCA ACT TA-3) or mutant (5-GAT CCT
GGG AAG TTG CTG AGA ACA ACT TA-3) sequences spanning nt
117 to 94 of human apoAV promoter into the BglII site of pGL3-TK.
Plasmids expressing human cDNAs for TR1 and TR1 were provided
by J. A. Holt (GlaxoSmithKline, Research Triangle Park, NC). Plasmid
DNA was prepared using the Qiagen endotoxin-free maxipreparation
method and quantified spectrophotometrically. The integrities of all
plasmids were verified by DNA sequencing.
Cell Transfection and Reporter Assays—Human hepatoblastoma
HepG2 cells were cultured in Eagle’s basal medium supplemented with
nonessential amino acids, 2 mM L-glutamine, 100 units/ml penicillin,
100 g/ml streptomycin sulfate (medium A), and 10% (v/v) fetal calf
serum. On day 0, cells were seeded on 24-well plates at a density of
3.5  105 cells/well. On day 1, cells were transfected with FuGENE 6
reagent (Roche Applied Science) according to the manufacturer’s in-
structions. Typically, each well of a 24-well plate received 200 ng of
firefly luciferase reporter plasmid and 100 ng of a plasmid expressing
human TR1, TR1, and/or USF. Effector plasmid dosage was kept
constant by the addition of appropriate amounts of the empty expres-
sion vector pSG5. 100 ng/well of a sea pansy (Renilla reniformis) lucif-
erase plasmid pRL-null (Promega) was included in all transfections as
an internal control for transfection efficiency. On day 2, cells were
switched to Dulbecco’s modified Eagle’s medium/F-12 medium (Invitro-
gen) supplemented with nonessential amino acids, 2 mM L-glutamine,
100 units/ml penicillin, and 100 g/ml streptomycin sulfate (medium B)
and 1% (v/v) delipidated calf serum (Sigma) and containing, when
indicated, T3 (Sigma), N-[3,5-dimethyl-4-(4-hydroxy-3-isopropylphe-
noxy)-phenyl]-oxamic acid (CGS-23425) (Novartis), or vehicle (water or
Me2SO, respectively). On day 3, cell lysates were prepared by shaking
the cells in 200 l of 1 Promega lysis buffer for 15 min at room
temperature. Firefly and Renilla luciferase activities were measured
using a Dual-Luciferase® reporter assay system (Promega) and a Lu-
mistar luminometer (BMG Lab Technologies). Firefly luciferase activity
values were divided by Renilla luciferase activity values to obtain
normalized luciferase activities. To facilitate comparisons within a
given experiment, activity data were presented either as relative lucif-
erase activities or as -fold induction over the normalized activity of the
reporter plasmid in the absence of nuclear receptor cotransfection and
agonist supplementation. The data are expressed as the means  S.D.
Statistic significance analyses were done with Student’s t test.
Cell Treatments—On day 0, human hepatoblastoma HepG2 cells or
rat hepatoma McArdle-RH7777 (ATCC, Manassas, VA) were plated on
24-well plates at 5 105 or 105 cells/well, respectively, in medium A and
10% (v/v) fetal calf serum or in Dulbecco’s modified Eagle’s medium
supplemented with 4.5 g/liter glucose, 2 mM L-glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin sulfate, 10% (v/v) fetal bovine serum,
and 10% (v/v) horse serum, respectively. On day 2, cells were refed with
medium B supplemented with 1% (v/v) delipidated calf serum (Sigma),
and T3 (Sigma), CGS-23425 (Novartis) or vehicle (water or Me2SO,
respectively). On day 3, cells were washed twice with PBS and har-
vested for isolation of RNA or Western analysis. Human primary hepa-
tocytes in 24-well plates fed with Williams E medium supplemented
with 100 nM dexamethasone, 100 units/ml penicillin, 100 g/ml strep-
tomycin sulfate, 4 g/ml insulin (medium C), and 1% (v/v) fetal calf
serum were provided on day 0 by Biopredict (batch Hep220069 MW24).
On day 1, cells were refed with medium C supplemented with 1% (v/v)
delipidated calf serum and containing 50 nM T3, 10 nM CGS-23425, or
vehicle (water or Me2SO, respectively). After 24 h, the medium was
replaced by 500 l/well fresh medium C containing 50 nM T3, 10 nM
CGS-23425, or vehicle (water or Me2SO, respectively). After 6 h, media
were collected, and the cells were washed twice with PBS and harvested
for isolation of RNA or Western analysis.
Western Blot Analysis—For determination of secreted apoAV, media
from triplicate wells were pooled, and proteins were precipitated by the
addition of 180 l of trichloroacetic acid (Sigma) and agitation overnight
at 4 °C. After centrifugation at 2  104 g at 4 °C for 15 min, protein
pellets were washed twice in 500 l of cold acetone, dried at room
temperature, and resuspended in 100 l of 1 NuPage LDS sample
buffer (Invitrogen). For determination of cellular apoAV, whole cell
lysates were prepared by shaking the cells on 24-well plates in 100
l/well lysis buffer A (PBS, 1% Triton, 50 mM NaF, 5 mM sodium
pyrophosphate, 10 l/ml protease inhibitor mixture from Sigma) for 30
min at 4 °C. The lysates were clarified by centrifugation at 104  g at
4 °C for 5 min.
60-l aliquots of resuspended samples from the incubation media
and 40 g of proteins from whole cell lysates were boiled at 100 °C for
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5 min, electrophoresed on 10% polyacrylamide MOPS NuPAGE® Novex
gels (Invitrogen), and transferred onto nitrocellulose membranes in
NuPAGE® transfer buffer (Invitrogen). Membranes were preincubated
for 1 h at room temperature in blocking buffer, 5% nonfat dry milk in
PBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% (v/v) Tween 20).
Subsequently, blots were incubated overnight at 4 °C with rabbit anti-
human apoAV, rabbit anti-rat apoAV (25), or mouse anti--actin
(A5441; Sigma) in blocking buffer. After washing five times in PBST for
5 min, blots were incubated with IRDye™ infrared dye 38 (800 nm;
Rockland Immunochemicals) and Alexa Fluor® 680 (700 nm; Molecular
Probes, Inc., Eugene, OR) labeled goat anti-mouse and anti-rabbit sec-
ondary antibodies diluted at 1:5000 in PBST for 1 h at room tempera-
ture. Signals were detected by using Odyssey™ Infrared Imaging Sys-
tem (LI-COR).
Real-time PCR Quantification of mRNAs—Total RNA was prepared
from human primary hepatocytes, HepG2, and rat McArdle cells with
the RNeasyTM Mini kit, the QIAshredderTM homogenizers, and the
RNase-free DNase set (Qiagen) according to the manufacturer’s in-
structions. Human normal liver total RNA was purchased from BD
Biosciences (reference number 64099-1, batch 4120140; Caucasian 51-
year-old man, sudden death). A 1-g aliquot was used as a template for
cDNA synthesis employing the TaqManTM Reverse Transcription Rea-
gent kit (Applied Biosystems). Primers were designed with Primer
Express Software (PerkinElmer Life Sciences). The sequences of for-
ward and reverse primers used for the amplifications are as follows: 18
S, 5-GGG AGC CTG AGA AAC GGC-3 and 5-GGG TCG GGA GTG
GGT AAT TT-3; hTR1, 5-CAG CCG CTT CCT CCA CAT-3 and
5-CCG CCT GAG GCT TTA GAC TT-3; hTR1, 5-CTG CAC ATG
AAG GTG GAA TG-3 and 5-TCG AAC ACT TCC AGG AAC AA-3;
cyclophilin, 5-CAT CTG CAC TGC CAA GAC TGA-3 and 5-CCA CAA
TAT TCA TGC CTT CTT TCA-3; hAPOC3, 5-CTT CTC AGC TTC ATG
CAG GGT TA-3 and 5-ACG CTG CTC AGT GCA TCC TT-3; hLDLr,
5-GTT GCT GGC AGA GGA AAT GAG AAG-3 and 5-CAA AGG AAG
ACG AGG AGC ACG AT-3; hAPOA5, 5-AGC TGG TGG GCT GGA
ATT T-3 and 5-GGC CAC CTG CTC CAT CAG-3; and rAPOA5,
5-ACA CGG TCG AGC TGA TGG-3 and 5-GGC CTT GGT GCC TTT
TCC-3, respectively. The specificity and efficiency of the primers were
validated as previously described (35). The reactions contained 4 l of
diluted (1:10) cDNA, a 300 nM concentration of the forward and reverse
primers, and 2 SYBRTM Green PCR Master Mix (Applied Biosystems)
in a final volume of 20 l. Real-time PCRs were carried out in 384-well
plates by using the ABI PRISMTM 7900 sequence detection system
(Applied Biosystems). Levels of TR1 and TR1 were normalized by 18
S to compensate for variations in input RNA amounts. Levels of APOA5,
APOC3, and LDLr were normalized to cyclophilin to compensate for
variations in input RNA amounts (cyclophilin levels were unaffected by
the treatments). The amounts of mRNAs were calculated using the
comparative CT method as described in Ref. 38. All assays were per-
formed in triplicate during two independent experiments, and the re-
verse transcriptase (RT)-PCRs were carried out in duplicate for
each sample.
In Vitro Transcription/Translation and EMSAs—TR, RXR, USF1,
and USF2 proteins were synthesized in vitro from the expression
plasmid by using TNT® Quick Coupled transcription/translation sys-
tem (Promega) according to the instructions of the manufacturer. In
order to obtain an unprogrammed lysate as a negative control for
EMSA, a reaction was performed with the empty vector pSG5. Dou-
ble-stranded oligonucleotides corresponding to the sequence span-
ning nt 117 to 94 and nt 88 to 69 of human APOA5 promoter
(AVDR4 and AVEbox, respectively) or modified versions harboring
mutations in the DR4 hexamers and E-box described under “Plas-
mids” (mutAVDR4 and mutAVE, respectively) were radiolabeled by
fill in with the Klenow fragment of DNA polymerase I and used as
probes. The control probes contain the DR4 sequence of the human
TR proximal TR response element (39) and the E-box of the rat
CPT-I first intron (40), respectively. Protein-DNA binding assays
and electrophoreses of samples were performed as described (41).
Gels were dried and analyzed using a PhosphorImager STORM 860
and ImageQuant software (Amersham Biosciences).
Hypothyroid Rats—All experimental protocols were performed in
accordance with the policies of the institutional Animal Care and Use
Committee. 12-week-old male Wistar rats (Charles River France)
were housed under controlled conditions (22 °C, 12 h/12 h dark/light
cycle) with food and water ad libitum. Twelve rats were divided into
a control and an experimental group. The experimental group was
rendered hypothyroid by gavage with a daily single dose of 10 mg/kg
6-n-propyl-2-thiouracil (PTU) (Sigma) aqueous solution for 3 weeks.
Seventeen days after the initiation of the PTU treatment, the exper-
imental group received an intraperitoneal injection of saline (PTU,
n  4) or 300 g/kg T3 (PTU  T3, n  4) daily for 4 days. Control rats
(n  4) received daily gavage and intraperitoneal injection of only the
solvents for the same periods of time. Six hours after the final ad-
ministration, the animals were killed, and livers were excised. Liver
sections of 300 mg were placed in 4 ml of lysis buffer A and homog-
enized for 20–40 s using a conventional rotor-stator. The lysates were
clarified by centrifugation at 104  g at 4 °C for 5 min. 40 g of
protein were used for Western analysis.
CGS-23425 Treatment of Fat-fed Rats—Six-week-old male Sprague-
Dawley rats (Charles River France) were maintained on a chow diet
supplemented with 1.5% cholesterol and 0.5% cholic acid (fat-fed) for 14
days before experiments. Fat-fed rats were treated orally by gavage
with a daily single dose of 100 g/kg/day CGS-23425 (Novartis) or
vehicle (0.5% hydroxypropyl methylcellulose, 1% Tween 80) for 1 week.
Four hours after the last dose, the animals were killed, and blood and
livers were collected. Lysates from liver sections (300 mg) were pre-
pared as described above. Total plasma triglyceride levels were meas-
ured enzymatically using the TG-PAP150 kit (Biomerieux, France).
RESULTS
T3 and the Thyromimetic CGS-23425 Increase APOA5 Ex-
pression in Hepatocytes—APOA5 is expressed in human hepa-
toma HepG2 cells with levels comparable with human primary
hepatocytes (see Ref. 36 for a comparison). Although transla-
tional or posttranslational factors may ultimately regulate re-
ceptor content in cultured cells, we verified by quantitative
real-time RT-PCR that both TR1 and TR1 isoforms are ex-
pressed in HepG2 and human primary hepatocytes, suggesting
that both isoforms may be readily available for T3-dependent
regulation studies. More specifically, TR1 mRNA levels in
HepG2 are 4-fold higher than in human primary hepatocytes
and 5-fold higher than in human liver (2Ct 104 values were
7.00  0.53, 1.84  0.35, and 1.37  0.06, respectively),
whereas TR1 levels are similar in the three cases (2.33  0.12
for HepG2, 2.08  0.36 for human primary hepatocytes, and
2.91  0.05 for human liver). To determine whether T3 can
modulate APOA5 gene expression, we incubated HepG2 cells in
the presence or absence of T3. Treatment with T3 significantly
increased APOA5 mRNA levels at 6 h, and a 2-fold induction
was achieved after 24 h of T3 addition (Fig. 1A). Furthermore,
increasing concentrations of T3 resulted in a dose-dependent
induction of APOA5 expression (Fig. 1B). In addition, we aimed
to know whether APOA5 expression might be increased by TH
analogs with potential therapeutic interest (12). CGS-23425 is
a synthetic thyromimetic with cholesterol-lowering effects but
minimal cardiac toxicity in rats that has been reported to be
more selective toward TR1 versus TR1 and to show a higher
binding affinity to intact hepatic nucleic than T3 (42). As shown
in Fig. 1B, CGS-23425 increased APOA5 mRNA levels, attain-
ing a 2.2-fold increase at 5 nM.
Similarly, human primary hepatocytes and rat hepatoma
McArdle cells were incubated for 24 h in medium containing T3,
CGS-23425, or vehicle. As shown in Fig. 1, C–F, treatment with
T3 or CGS-23425 increased APOA5 mRNA levels. These effects
were specific, since the expressions of LDLr (Fig. 1, C and D)
and CPT-I (Fig. 1, E and F) were also increased, in accordance
with previous studies (40, 43), whereas cyclophilin, used as
internal control, remained unaffected by T3 or CGS-23425
treatments, and in addition, no significant effect on APOC3
mRNA levels was observed (Fig. 1, C and D).
T3 and the Thyromimetic CGS-23425 Increase ApoAV Protein
Levels in Human Hepatocytes—Western blot analyses performed
on whole cell lysates from HepG2 (data not shown) and human
primary hepatocytes (Fig. 2) incubated for 24 h with T3, CGS-
23425, or vehicle revealed that the quantity of cellular apoAV
protein was markedly increased by both TR ligands (Fig. 2).
Moreover, treatments with T3 or the thyromimetic CGS-23425
led to a significant increase in levels of apoAV protein secreted
into the medium by human primary hepatocytes (Fig. 2).
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T3 and CGS-23425 Increase Human APOA5 Expression at
the Transcriptional Level via the Nuclear Receptor TRs—To
determine whether APOA5 was directly responsive to T3-acti-
vated TRs, we performed functional analysis of the human
APOA5 promoter. In transient transfection assays in HepG2
cells, treatment with 50 nM T3 increased the activity of the
firefly luciferase reporter gene driven by the 617/18 se-
quence of the human APOA5 promoter (Fig. 3A). The effect of
T3 was promoter-dependent, because it was not observed with
the promoterless pGL3-basic vector. Cotransfection of human
TR1 or TR1 expression plasmids robustly enhanced T3-in-
duced promoter activity. In contrast, APOA5 promoter activity
was not affected significantly by cotransfection of TR1 or
TR1 in the absence of T3 (Fig. 3A). No statistically significant
differences on T3 induction of APOA5 promoter were observed
between TR1 and TR1 transactivations. In order to confirm
that the lipid-lowering thyromimetic CGS-23425 induces the
APOA5 gene at the transcriptional level, similar transient
transfection assays were performed in HepG2 cells with the
human APOA5 promoter along with a human TR1 expression
plasmid. As shown in Fig. 3B, increasing concentrations of
CGS-23425 resulted in a dose-dependent induction of the lucif-
erase activity. The promoterless pGL3-basic vector was unaf-
fected by CGS-23425 (data not shown).
FIG. 3. Transactivation of the human APOA5 gene promoter by
TR and T3. A, HepG2 cells were transfected with a plasmid contain-
ing a luciferase reporter gene driven by the 5-flanking region (617/
18) of the human APOA5 gene or the empty pGL3-basic vector along
with a plasmid expressing human TR1, TR1, or the empty vector
pSG5 as control. Cells were incubated in the absence (Control) or the
presence of 50 nM T3 for 24 h, and luciferase activities were measured
as described under “Experimental Procedures.” Results are expressed
as -fold induction over control. *, p	 0.005; **, p	 0.001 versus control.
The results are representative of three independent experiments. B,
HepG2 cells were transfected with a plasmid containing a luciferase
reporter gene driven by the 5-flanking region (617/18) of the human
APOA5 gene along with a plasmid expressing human TR1. Cells were
incubated with vehicle (0) or increasing concentrations of CGS-23425
for 24 h, and luciferase activities were measured as described under
“Experimental Procedures.” Results are expressed as -fold induction
over vehicle. The results are representative of three independent
experiments.
FIG. 1. T3 and the thyromimetic CGS-23425 increase APOA5
mRNA levels. A, human hepatoma HepG2 cells were incubated in the
absence (control) or the presence of 50 nM T3 for the indicated periods of
time (A) or in the presence of increasing concentrations of T3, CGS-
23425 or vehicle (water or Me2SO, respectively) for 24 h (B). Primary
hepatocytes isolated from adult human liver were treated for 24 h with
50 nM T3 (C), 10 nM CGS-23425 (D), or vehicle (Control or DMSO,
respectively). Rat hepatoma McArdle cells were treated for 24 h with
100 nM T3 (E), 100 nM CGS-23425 (F), or vehicle (Control or DMSO,
respectively). Total RNA was extracted for analysis by real-time RT-
PCR as described under “Experimental Procedures.” Specific APOA5,
APOC3, LDLr, and CPT-I mRNA levels normalized to cyclophilin
content are expressed as 2Ct and relative to untreated cells set as 1
(mean S.D.). Significant differences compared with the corresponding
untreated controls are as follows: *, p	 0.005; **, p	 0.001. The results
are representative of two or three independent experiments.
FIG. 2. T3 and the thyromimetic CGS-23425 increase apoAV
protein secretion in primary human hepatocytes. On day 1, pri-
mary hepatocytes isolated from adult human liver were incubated in
the presence of 50 nM T3, 10 nM CGS-23425, or vehicle (Control or
DMSO, respectively). On day 2, cells received fresh media containing
the same treatments, respectively. After 6 h, media and cells were
collected, and protein content was analyzed by Western blot as de-
scribed under “Experimental Procedures.” Experiments were per-
formed two times, and a representative result is shown.
APOA5 Regulation by T327536
A DR4 Element in the Human APOA5 Promoter Is Required
for Transcriptional Activation by TR—To localize the region
within APOA5 that confers transcriptional responsiveness to
T3-activated TR, a series of constructs containing sequential
5-deletions from nt 1422 to 18 of the human APOA5 pro-
moter in front of the firefly luciferase reporter gene were tran-
siently transfected into HepG2 cells together with a human
TR1 expression plasmid in the presence or the absence of 50
nM T3. As shown in Fig. 4A, the sequence upstream to position
242 could be removed without preventing strong activation of
the reporter gene by T3-activated TR. In contrast, deletion
of the fragment between nt242 and82 completely abolished
the induction of APOA5 promoter activity by T3-activated TR,
indicating that this region mediates the effects of T3. Analysis
of the sequence in the 242/82 fragment revealed a direct
repeat of the hexanucleotide core motif PuGGTCA with a low
degree of degeneration separated by 4 nucleotides between nt
113 and 98 (Fig. 4B), thereby conforming to the DR4 re-
sponse element for TR (TRE).
To unequivocally characterize this DR4 as the functional
TRE required for T3 induction of APOA5, HepG2 cells were
cotransfected with a human TR1 expression vector and an
APOA5 promoter-luciferase reporter plasmid in which the DR4
sequence was mutated (Fig. 4B). In contrast to the wild-type
promoter construct, T3 and T3-activated TR1 failed to induce
the activity of the construct bearing the mutated DR4 (Fig. 4C).
The RXR-TR Heterodimer Binds Specifically to the APOA5
DR4 Element—Direct binding of RXR-TR heterodimers to the
APOA5 DR4 element was examined. For this purpose, gel shift
assays were performed using in vitro translated human RXR
and TR and radiolabeled double-stranded oligonucleotides
containing the wild-type or a mutated version of the APOA5
DR4 element. The addition of TR1 resulted in the appearance
of a weak protein-DNA complex band (Fig. 5, lane 7). This
phenomenon most likely corresponds to the binding of TR1
monomers and is also perceived with a control probe containing
the DR4 sequence of the human TR proximal TRE (Fig. 5, lane
3) (34). However, when both RXR and TR1 were present, this
faint band disappeared, and a robust and more shifted band
emerged (Fig. 5, lane 8). In contrast, a labeled probe that is
equivalent to APOA5 DR4 but harbors point mutations in the
half-sites could not form the faster mobility band with TR1 or
the strong RXR-TR binding complex (Fig. 5, lanes 11 and
12). Furthermore, the specificity of the RXR-TR1-APOA5
DR4 interaction was confirmed by competition analysis using
an excess of cold double-stranded oligonucleotides correspond-
FIG. 4. Identification and characterization of a TR response element in the human APOA5 promoter. A, localization of a TR response
region by progressive deletion analysis. HepG2 cells were cotransfected with reporter plasmids containing the firefly luciferase gene driven by
progressively 5-shortened fragments of the APOA5 promoter as indicated, together with the empty vector pSG5 or a plasmid expressing human
TR1. Cells were incubated in the absence or the presence of 50 nM T3 for 24 h, and luciferase activities were measured as described under
“Experimental Procedures.” Results in the histogram are expressed as -fold induction over control. Values of normalized relative luciferase
activities (RLU) for the different constructs in basal conditions are shown in the column to the left of the histogram and are expressed as the
mean S.D. The results are representative of three independent experiments. B, human APOA5 promoter sequence surrounding the DR4 element.
The gray box denotes the DR4 sequence. The AGGTCA half-sites are indicated by horizontal arrows. The wild-type nucleotides that were modified
by site-directed mutagenesis are underlined. The corresponding 109C3T/108A3T/101G3A/100T3A mutated nucleotides are shown
below the vertical arrow and within the gray squares. C, mutation of the DR4 element on the human APOA5 promoter eliminates the response to
T3–activated TR1. Experiments were performed as in A with reporter constructs containing the wild-type or site-directed mutated APOA5
promoter or the empty pGL3-basic vector as negative control. The cross depicts the presence of site-directed mutations in the DR4 element. LUC,
luciferase. The results are representative of three independent experiments.
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ing to the control DR4 probe, which inhibited the retarded
complex, and the mutated APOA5 DR4, which failed to displace
the labeled wild-type element (data not shown). Additional
EMSAs showed that no TR1 monomers or RXR-TR1 het-
erodimers could bind when the downstream half-site was mu-
tated, whereas mutation of the upstream hexamer markedly
diminished heterodimer binding but enhanced the binding of
TR monomers (data not shown), thereby suggesting that RXR
binds to the upstream and TR1 to the downstream hexamer,
respectively, of APOA5 DR4, as a classical direct repeat
TRE (44).
The APOA5 DR4 Element Confers TR Responsiveness to Het-
erologous Promoters—To evaluate whether this DR4 element
could confer T3-activated TR responsiveness to a heterologous
promoter, we linked the APOA5 DR4 site upstream of the TK
promoter and the luciferase gene. Reporter constructs contain-
ing one, two, three, and five copies of this motif were tran-
siently transfected into HepG2 cells along with a human TR1
expression plasmid in the presence or the absence of T3. As
demonstrated in Fig. 6, T3-activated TR1 enhanced the activ-
ity of APOA5 DR4-driven promoter constructs, whereas the
reporter constructs with the TK promoter alone or driven by
several copies of mutated APOA5 DR4 were not stimulated.
Indeed, an 80-fold induction was attained with five copies, and
the response was manifested in a copy number-dependent man-
ner. In addition, we observed that the APOA5 DR4 site con-
ferred 2-fold more T3-activated TR1 responsiveness to the TK
promoter than the CPT-I DR4 TRE (data not shown). Taken
together, these results show that this APOA5 DR4 motif is a
genuine TRE.
The USF Transcription Factors Cooperate with TR in the
T3-mediated Induction of APOA5—As shown in Fig. 7A, there
is a nearby sequence 5-CACGTG-3 downstream of this DR4
element that constitutes a canonical E-box motif, a binding site
for basic helix-loop-helix/leucine zipper proteins. Recently, it
was reported that this E-box might make a minor contribution
to the sterol regulatory element-binding protein-1c-mediated
down-regulation of APOA5 (36). Inasmuch as USF transcrip-
tion factors appear to be the predominant basic helix-loop-
helix/leucine zipper proteins in liver nuclear extracts (45) and
because they can physically interact with TR (40), we set out to
investigate whether USF might be involved in the T3 induction
of APOA5 through this E-box.
EMSAs were conducted using double-stranded oligonucleo-
tides that corresponded to the wild-type or a mutated version of
the 88/69 sequence in human APOA5. USF1 (data not
shown) and USF2 bound to the wild-type APOA5 E-box con-
taining probe (Fig. 7B, lane 2) but not to the equivalent version
that harbors 80A3C/77T3C point mutations (Fig. 7B,
lane 4). Furthermore, competition analysis showed that the
retarded complex was inhibited by an excess of an unlabeled
control probe (Fig. 7B, lanes 8–10), containing the E-box of
CPT-I (40), but not by the mutated APOA5 E-box probe (data
not shown).
Transient transfection assays in HepG2 cells revealed that
USF activates at least 2-fold the luciferase reporter gene ex-
pression vector driven by the617/18 sequence of the human
APOA5 promoter (Fig. 7C). In the absence of T3, cotransfection
of TR1 produced no effect. However, in the presence of T3, TR
and USF synergistically activate APOA5, attaining a 20-fold
induction (Fig. 7C). Furthermore, as shown in Fig. 8A, an
internal deletion USF mutant lacking the basic region required
for DNA binding (UB), which forms dimers and sequesters
both endogenous USF1 and USF2 (46), down-regulated APOA5
promoter activity both in the absence and in the presence of T3
and transfected TR1. Likewise, an N-terminal truncated USF
mutant (UN), composed only of the basic region and basic
helix-loop-helix/leucine zipper domains and which binds DNA
and forms dimers but is totally inactive (47), also reduced
APOA5 promoter activity. Therefore, both the DNA binding
FIG. 5. TR-RXR heterodimers can bind specifically to the DR4
element of the APOA5 promoter. EMSAs were performed using in
vitro transcribed/translated human TR1 (2.5 l), human RXR (2.5
l), or unprogrammed reticulocyte lysate (), when indicated, and
labeled double-stranded oligonucleotides corresponding to the sequence
spanning nt 117 to 94 of human APOA5 promoter (AVDR4) or a
modified version harboring mutations in the DR4 hexamers correspond-
ing to nt 109C3T/108A3T/101G3A/100T3A (mutAVDR4) as
described under “Experimental Procedures.” Control corresponds to the
DR4 sequence of the human TR proximal TRE (34). The lysate vol-
umes were kept constant by the addition of unprogrammed lysate.
TR1-DR4 and TR1/RXR-DR4 complexes are indicated by arrows.
Note that the faint retarded bands of probe mutAVDR4 (lanes 9–12) are
nonspecific. Experiments were performed two times, and a represent-
ative result is shown.
FIG. 6. The DR4 element present in the APOA5 promoter con-
fers TR responsiveness to heterologous promoters. HepG2 cells
were transiently transfected with plasmids expressing human TR1 or
the empty pSG5 vector as control, together with reporter constructs
containing 1–5 copies of the wild-type (AVDR4) and three or five copies
of mutant (mutAVDR4) sequence corresponding to nt 117 to 94 of
the APOA5 promoter cloned in front of a heterologous TK promoter-
driven luciferase. The empty pGL3-TK reporter vector was used as
negative control. Cells were incubated in the absence or the presence of
50 nM T3 for 24 h, and luciferase activities were measured as described
under “Experimental Procedures.” Results are expressed as -fold induc-
tion over control. The results are representative of three independent
experiments.
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and the transcriptional activation domains of USF are required
for full synergistic activation with T3-activated TR1. Never-
theless, it is worth noting that, in the presence of both TR and
UN, the magnitude of -fold induction by T3 was similar to that
achieved in the presence of TR and the wild-type USF (Fig. 8A,
compare data of T3/Cont). These findings suggest that despite
the fact that this USF mutant lacking the N-terminal activa-
tion domain represses APOA5, probably due to competition
with the endogenous active USF (47), the enhanced response to
T3 is somehow linked to the ability of USF to bind to DNA.
In order to better assess the importance of the binding of
USF on the enhancement of the T3 induction of APOA5, we
introduced the mutations that had been shown to disrupt USF
binding to the E-box in gel shift assays (Fig. 7B) in the 617/
18 construct, leaving an intact DR4, and performed transfec-
tion assays. As expected, USF failed to activate the construct
bearing the mutated E-box (Fig. 8B). This finding indicates
that the E-box at 81/76 is required for the USF response
and also that another E-box present at10 alone is not enough
to confer USF responsiveness. Accordingly, the mutation of the
USF binding site abolished the synergism between T3-acti-
vated TR1 and USF, thereby confirming that the binding of
USF to DNA is required for the action of USF on T3 induction
(Fig. 8B).
ApoAV Content Correlates with Thyroid Status in Rats—In
order to extend our analyses to animal models, we chemically
induced hypothyroidism in rats by the well described treat-
ment with PTU, which inhibits the 5-deiodinase enzyme re-
quired to convert the 3,5,3,5-tetraiodo-L-thyronine (T4) form
of TH into the more bioactive T3 isoform (48). Under these
conditions, plasma T4 levels fall significantly by 75–90%, and
there is also an 60% reduction of plasma T3 (49–51), whereas
plasma thyroid-stimulating hormone concentrations rise (52).
As shown in Fig. 9, apoAV protein levels were dramatically
diminished in the hypothyroid rats, whereas actin levels re-
mained unaltered. However, administration of T3 restored
apoAV protein abundance (Fig. 9). Together, these data dem-
onstrated that apoAV strongly correlates with thyroid status.
The Thyromimetic CGS-23425 Increases ApoAV Protein Lev-
els in Rats—The TR-selective agonist CGS-23425 has been
found to exert lipid lowering actions in fat-fed rats (42). Thus,
we examined the effects of this thyromimetic on hepatic apoAV
levels in fat-fed rats treated with a daily single dose of the drug
for 1 week. As expected, CGS-23425 increased the levels of
apoAV protein, whereas actin content was unaffected (Fig.
10A). Furthermore, we observed that this TR-selective ago-
nist induced a dramatic decrease both in VLDL-TG (44% of
controls, data not shown) and in total plasma TG concentra-
tions (Fig. 10B).
DISCUSSION
Clinical observations showing inverse correlation between
the degree of triglyceridemia and thyroid status (4–8, 11) cou-
pled with the fact that APOA5 is a major determinant of TG
homeostasis (24–32) prompted us to explore the potential reg-
ulation of this recently identified gene by TH. Our present
FIG. 7. USF can bind to the E-box present in the APOA5 promoter and synergistically activate the T3-activated TR induction of
APOA5. A, schematic representation showing the TRE (DR4) and the USF binding element (E-box) in the nucleotide sequence corresponding to
the 5 region of the human APOA5 gene. Numbers are relative to the transcription start site (1). The hexameric half-sites in the DR4 element
are indicated by horizontal arrows. B, EMSAs were performed using in vitro transcribed/translated USF2 () or unprogrammed reticulocyte lysate
(), when indicated, and labeled double-stranded oligonucleotides corresponding to the sequence spanning nt 88 to 69 of human APOA5
promoter (AVEbox) or a modified version harboring80A3C/77T3C point mutations (mutAVE) as described under “Experimental Procedures.”
Control corresponds to the E-box sequence of rat CPT-I (35). The lysate volumes were kept constant by the addition of unprogrammed lysate.
USF-E-box complexes are indicated by an arrow. The competition experiments for binding of USF2 to the labeled probe AVEbox were performed
by adding a 10-, 50-, and 250-fold molar excess of the unlabeled CPT-I E-box oligonucleotides (CONT). EMSAs were performed two times, and
a representative result is shown. C, HepG2 cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5-flanking
region (617/18) of the human APOA5 gene or the empty pGL3-basic vector together with plasmids expressing USF2, TR1, or the empty vector
pSG5 as control. Cells were incubated in the absence or the presence of 50 nM T3 for 24 h, and luciferase activities were measured as described
under “Experimental Procedures.” Results are expressed as -fold induction over control. *, p 	 0.005; **, p 	 0.001 versus control. Similar results
were obtained with USF1. The histograms are average values from three independent transfections, with each point conducted in triplicate.
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findings demonstrate that T3 directly up-regulates expression
of the hypotriglyceridemic gene APOA5. Our experiments in
hepatocytes revealed an increase in APOA5 mRNA levels and
in both cellular and secreted apoAV protein by T3 and a lipid-
lowering synthetic thyromimetic. Transient transfection exper-
iments indicated that T3 may increase APOA5 expression at
the transcriptional level via both TR1 and TR1 isoforms. As
demonstrated by EMSA and mutation analyses, activation by
T3 may be attributed to a DR4 element located within the
proximal APOA5 promoter. Our data from transfection assays
using the isolated APOA5 DR4 showed that this TRE is capable
of conferring positive T3 responsiveness to a heterologous pro-
moter, further confirming that this DR4 motif corresponds to a
genuine TRE. Taken together, our results demonstrate that
APOA5 is a direct target of TH.
We have ascertained that USF and TR synergistically acti-
vate APOA5 in a ligand-dependent manner. We do not know
the exact mechanisms implicated in this ligand-dependent syn-
ergism at this time. Interestingly, it has been shown that TR
can physically interact with USF1 and USF2 (40). In addition,
although T3 induction of APOA2 mRNA or protein abundance
is yet to be reported, Kardassis and co-workers (53) have shown
a synergistic interaction between TR and USF in the APOA2
promoter. These authors hypothesized that USF might regu-
late the TR transcriptional activity by DNA binding-dependent
and -independent modes; thus, it might regulate promoters
that contain TREs but not necessarily USF binding sites (53).
Two evidences suggest that this is not the case of APOA5. First,
the DNA binding domain of USF is required for the synergism
with TR in the T3 induction of APOA5. Second, when the USF
binding site in APOA5 was mutated, USF had no effect in the
presence of TR and T3, thereby indicating that a DNA-binding
mechanism is necessary for the synergistic action of USF on
T3-activated TR induction of APOA5.
On the other hand, although USF greatly enhances the T3
stimulation of APOA5, several observations suggest that the
dependence on USF is not straightforward. First, the APOA5
TRE alone is sufficient to support a robust response to T3 when
linked to a basal heterologous promoter. Second, cotransfection
of a mutant USF that lacks the DNA-binding domain dimin-
ishes the APOA5 promoter activity, probably due to the seques-
tration of endogenous USF (46), but it produces no significant
decrease in the -fold induction by T3 in the presence of TR (5.8
versus 6.0 in Fig. 8A). Furthermore, mutational analyses of the
E-box show that the induction by T3-activated TR is similar in
both wild-type and mutant constructs. Hence, this E-box is
absolutely required for the ligand-dependent synergism be-
tween TR and USF, but it appears not to be necessary for the
sustenance of T3 response. A similar situation has been de-
scribed between sterol regulatory element-binding protein and
the ubiquitous factor Sp1 in the FAS promoter (54). Whereas
sterol regulatory element-binding protein and Sp1 synergisti-
cally activate the FAS promoter, mutational analyses revealed
that the Sp1 site is dispensable for sterol regulation (54).
While this manuscript was in preparation, Nowak et al. (55)
reported that insulin down-regulates APOA5 expression via
USF. Interestingly, in agreement with our study, these authors
show by chromatin immunoprecipitation assays that the E-box
at 81/76 may bind USF. Even more interestingly, the com-
bination of their report and our study raises the possibility of a
cross-talk between insulin and thyroid signals on the same
element in APOA5.
Strikingly, USF1 has been recently identified as the gene on
human 1q21–23 that is associated with familial combined hyper-
lipidemia and especially with high triglycerides in men (56).
Therefore, additional studies are warranted to address the rele-
FIG. 8. Functional evaluation of the
contribution of USF transcriptional
activation and DNA-binding do-
mains, and the APOA5 E-box to the
T3-dependent synergism between
USF and TR. A, HepG2 cells were trans-
fected with a plasmid containing a lucif-
erase reporter gene driven by the 5-
flanking region (617/18) of the human
APOA5 gene or the empty pGL3-basic
vector together with plasmids expressing
full-length USF2 (USF), an internal-dele-
tion mutant of USF2 lacking the basic
region required for DNA binding (UB),
an N-terminal truncated USF2 lacking
the activation domain (UN), TR1, or
the empty vector pSG5 as control ().
Cells were incubated in the absence (Con-
trol) or the presence of 50 nM T3 for 24 h,
and luciferase activities were measured
and expressed as described under “Exper-
imental Procedures.” Control levels for
each reporter plasmid are set as 1. -Fold
inductions by T3 are indicated (T3/Cont).
B, the E-box at 81 is required for the
synergism between USF and T3-activated
TR1. Experiments were performed as in
A with reporter constructs containing the
wild-type or site-directed mutated APOA5
promoter. The cross depicts the presence
of 80A3C/77T3C point mutations in
the E-box site. LUC, luciferase. Results
are expressed as -fold induction over con-
trol. The histograms are average values
from two independent transfections, with
each point conducted in triplicate.
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vance of USF-mediated regulation of APOA5 and other lipid-
related genes in familial combined hyperlipidemia phenotype.
We sought to extend our analyses of TH-mediated regulation
to animal models in vivo. However, the rat and mouse, commonly
used animals for T3 and TR studies, differ from humans in their
response to T3. Whereas LPL activity positively correlates with
TH levels in humans (9, 11), hypothyroidism in rats increases
both adipose and heart LPL mass and activity via a translational
mechanism involving its 3-untranslated region (57), whereas T3
reverses these effects (58). Accordingly, PTU-induced hypothy-
roidism in rats has been associated with reductions in plasma TG
(49, 50, 59, 60). Nevertheless, despite these overall effects, a
number of indirect observations suggest the existence of an un-
derlying hypotriglyceridemic response to T3 in rodents. First,
liver TG content decreases in hyperthyroid rats (61) and is in-
creased in congenitally hypothyroid mice (62). Second, there is a
lower secretion rate of VLDL by perfused livers from hyperthy-
roid rats, but the reverse occurs in hypothyroidism (63). Finally,
serum TG clearance was significantly hastened by treatment
with the TR ligand CGS-23425 in fat-fed rats (64). Our results
show that PTU-induced hypothyroidism reduced apoAV content,
whereas T3 treatment restored normal levels, thereby indicating
that thyroid status strongly correlates with apoAV levels in rats.
Consistent with previous reports, we observed that TG levels
were reduced in PTU-treated rats (data not shown). This paradox
probably has functional implications, since it suggests that a
decrease in apoAV does not necessarily impede an overall reduc-
tion of TG levels in hypothyroid rats, which is most likely due to
the translational increase in adipose and heart LPL mass re-
ported by others (57). On the other hand, we observed that
treatment with CGS-23425 at a heart-sparing dose (42) increased
apoAV content and decreased plasma TG levels in fat fed rats.
This finding is consistent with the TG-lowering effects exhibited
by the hepatoselective thyromimetic SK&F L-94901 in euthyroid
rats (65) and by the TR-selective agonist GC-1 in hypothyroid
mice (66). Although these data warrant further functional explo-
ration, we and others (65, 66) hypothesize that the hypotriglyc-
eridemic effects of these thyromimetics are most likely due to TR
subtype-specific and organ-selective causes. Indeed, SK&F
L-94901 does not discriminate TR subtype in terms of binding
affinity, but it is more effectively transported to the nucleus in
hepatic cells (67); GC-1, which has a 10-fold reduced affinity for
TR1, distributes primarily to the liver rather than to the heart
or the adipose tissue (66); and the TR-selective ligand CGS-
23425 is also markedly hepatoselective (42). Since TR1 is the
predominant isoform in adipose tissue (68), it is tempting to
speculate that the tissue-selective properties of these thyromi-
metics contribute to a loss of effect on adipose LPL translation,
whereas they induce the expression of hepatic genes such as
APOA5. Given the two hypotriglyceridemic mechanisms sug-
gested for apoAV (namely reduction in hepatic VLDL-TG secre-
tion rate (32, 69) and elevation in the efficiency of LPL-mediated
TG hydrolysis (32, 70)), the increase in apoAV that we observed
in rats is consistent with studies showing lower secretion rates of
VLDL in hyperthyroid rats (63), accelerated TG clearance in
CGS-23425-treated rats (64), and lower plasma TG concentra-
tions in thyromimetic-treated rodents (65, 66) (this study). On
the other hand, GC-1 has been reported to suppress thyroid-
stimulating hormone by 40% and to reduce plasma T4 levels by
35% at therapeutic doses, but this was not accompanied by a
statistically significant reduction in plasma T3 levels in rats (71).
Whereas the administered GC-1 would compensate in terms of
TR stimulation, it may not appreciably activate TR1, which
could therefore cause a relative TR hypothyroidism. It is not
known whether CGS-23425 modifies T3, T4, and thyroid-stimu-
lating hormone plasma levels in rats; future work may address
FIG. 10. Treatment with the TR agonist CGS-23425 increases
apoAV and reduces total TG in fat-fed rats. Fat-fed rats were
treated with solvent (Control) or 300 g/kg/day CGS-23425 for 7 days.
A, 40 g of protein from liver lysates were analyzed by Western blot as
described under “Experimental Procedures.” A representative blot is
shown. Protein signals were quantified by using Odyssey™ software,
and apoAV levels were normalized to -actin content. B, total plasma
TG levels were determined by enzymatic methods. The data are ex-
pressed relative to untreated animals set as 1 and represent the
mean  S.D. of six animals/group. *, p 	 0.005 versus control. The
results are representative of two independent experiments.
FIG. 9. Hypothyroidism diminishes and T3 treatment restores
apoAV levels in rat. Adult male rats were rendered hypothyroid by
administration of PTU for 3 weeks. For the last 4 days, rats were
treated with vehicle (PTU) or 300 g/kg/day T3 (PTUT3). Control rats
received only vehicles for the same periods of time (Control). 40 g of
protein from liver lysates were analyzed by Western blot as described
under “Experimental Procedures.” Signals were quantified by using
OdysseyTM software. ApoAV levels normalized to -actin content are
expressed relative to untreated animals set as 1 and represent the
mean  S.D. of four animals/group. *, p 	 0.005 versus vehicle PTU-
treated rats.
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the significance of these potential influences.
The molecular mechanisms implicated in the TG-lowering
effects of TH in humans are currently unclear. Although the
proximal promoter of the human APOC2, which encodes an
LPL cofactor, could be transactivated by RXR-TR heterodimers
(72), there are no data to indicate stimulation of APOC2 ex-
pression by TH. Similarly, it has been shown that RXR-TR
heterodimers bind with low affinity to the distal regulatory
region of the human APOC3 gene (73), an inhibitor of LPL-
mediated lipolysis, although regulation of human APOC3 ex-
pression by T3 has not been previously reported. Indeed, our
results in human hepatocytes suggest that the effect of T3 on
APOC3, if any, should be minimal. On the other hand, TH
regulates hepatic apoB mRNA editing in neonatal mice (62)
and rats (64), an effect that has been linked to increased he-
patic TG secretion (62). However, since apobec-1 is not ex-
pressed in human liver, these findings may not be extended
to humans.
The current results may provide a potential explanation for
the low VLDL-TG clearance rates and low LPL activity ob-
served in hypothyroid patients (6, 9) and for the increase in
LPL activity observed in TH therapies (9, 11).
In conclusion, our data reveal that treatment with T3 and
pharmacological activation of TR up-regulates APOA5 expres-
sion, thereby establishing a novel molecular pathway of T3
action. These results underscore a physiological role of TR in
the regulation of genes involved in triglyceride metabolism
and, therefore, identify TR as a potential pharmacological
target for the treatment of hypertriglyceridemia.
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